Menstrual disorders in adolescents: Review of current practice

Hormone Research in Paediatrics

Volumn 78, Issue 3, 2012, Pages 135-143

  Williams, Cara E ^a   Creighton, Sarah M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Dysmenorrhoea; Irregular periods; Menorrhagia

Indexed keywords

ADOLESCENT; ADULT; FEMALE; HUMANS; MENSTRUATION DISTURBANCES;

EID: 85027925404     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000342822     Document Type: Review

References (57)

1. Parker M, Sneddon A, Arbon P: The menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large populationbased study of Australian teenagers. BJOG 2010; 117: 185-192.
2. Boswell HB: The adolescent with menorrhagia: why, who and how to evaluate for a bleeding disorder. J Pediatr Adolesc Gynecol 2011; 24: 228-230.
3. Venturoli S, Porcu E, Fabbri R, Pluccinetta V, Ruggeri S, Macrelli S, Paradisi R, Flamigni C: Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Paediatr Res 1995; 38: 974-980.
4. Sanguin S, Lanta-Delmas S, Le Blanche A, Grardel-Chambenoit E, Merviel P, Gondry J, Fauvet R: Uterine arteriovenous malformations: diagnosis and treatment in 2011. Gynecol Obstet Fertil 2011; 39: 722-727.
5. Stavroulis AI, Saridogan E, Creighton SM, Cutner AS: Laparoscopic treatment of endometriosis in teenagers. Eur J Obstet Gynecol Reprod Biol 2006; 125: 248-250.
6. Laufer MR, Goitein L, Bush M, Cramer DW, Emans SJ: Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10: 199-202.
7. National Institute for Health and Clinical Excellence: Heavy Menstrual Bleeding (NICE Clinical Guideline 44). 2007. http://www. nice.org.uk/nicemedia/ live/11002/30401/30401.pdf.
8. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT: Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. BJOG 1998; 105: 592-598.
9. Lethaby A, Irvine G, Cameron I: Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;CD001016.
10. British National Formulary 2012. 6.4.1.2 Progestogens. http://www.medicinescomplete.com/mc/bnf/current/4336.htm#-4336.2.
11. Rajput R, Dhuan J, Agarwal S, Gahlaut PS: Central venous sinus thrombosis in a young woman taking norethindrone acetate for dysfunctional uterine bleeding: case report and review of literature. J Obstet Gynaecol Can 2008; 30: 680-683.
12. Lapecorella M, Orecchioni A, Dell'Orso L, Mariani G: Upper extremity deep vein thrombosis after suspension of progesterone-only oral treatment. Blood Coagul Fibrinolysis 2007; 18: 513-517.
13. Lidegaard O, Lokkegaard E, Svendsen AL, Agger CA: Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.
14. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, casecontrol study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57: 315-324.
15. British National Formulary for Children 2011-2012, pp 377-379.
16. Kovacs G: Progestogen-only pills and bleeding disturbances. Hum Reprod 1996; 11: 20-23.
17. British National Formulary for Children 2011-2012, pp 403-404.
18. Fraser IS, McCarron G: Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust NZ J Obstet Gynaecol 1991; 31: 66-70.
19. Hendrix SL, Alexander NK: Primary dysmenorrhoea treatment with a desogestrelcontaining low-dose oral contraceptive. Contraception 2002; 66: 393-399.
20. Collaborative Group on Epidemiological Studies of Ovarian Cancer: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314.
21. Jick SS, Walker AA, Jick H: Oral contraceptives and endometrial cancer. Obstet Gynecol 1993; 82: 931-935.
22. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E: Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 84: 722-727.
23. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM: Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011;CD003987.
24. Dinger JC, Heinemann LAJ, Kuhl-Habichl D: The safety of drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 womenyears of observation. Contraception 2007; 75: 344-354.
25. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS: Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-1195.
26. Medicines and Healthcare Products Regulatory Agency: Current Key Information on the Combined Oral Contraceptive, Yasmin-May 2011. Safety Warnings and Messages for Medicines. 2011. http://www.mhra.gov. uk/Safetyinformation/ Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON117560.
27. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF: 20g versus 1 20g estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2011; CD003989.
28. Faculty of Sexual and Reproductive Healthcare: UK Medical Eligibility Criteria for Contraceptive Use. 2009. http://www.fsrh. org/pdfs/UKMEC2009.pdf.
29. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
30. Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a metaanalysis. J Clin Endocrinol Metab 2005; 90: 3863-3870.
31. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 346: 505-510.
32. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T: Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339:b3914.
33. Curtis KM, Mohllajee AP, Martins SL, Peterson HB: Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 2006; 73: 179-188.
34. Faculty of Sexual and Reproductive Healthcare: Clinical Guideline. Combined Hormonal Contraception. October 2011. http://www.fsrh.org/pdfs/ CEUGuidanceCombinedHormonalContraception. pdf.
35. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
36. Gaffield ME, Culwell KR, Ravi A: Oral contraceptives and family history of breast cancer. Contraception 2009; 80: 372-380.
37. Sabers A, Buchholt JM, Uldall P, Hansen EL: Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151-154.
38. British National Formulary for Children 2011-2012, pp 396-402.
39. Lethaby A, Farquhar C, Cooke I: Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2009;CD000249.
40. Bonnar J, Sheppard BL: Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ 1996; 313: 579-582.
41. Sundström A, Seaman H, Kieler H, Alfredsson L: The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009; 116: 91-97.
42. British National Formulary for Children 2011-2012, p 123.
43. http://www.medicines.org.uk/EMC/medicine/24513/SPC/ Mefenamic+Acid+250mg+Capsules/.
44. Nilsson CG, Lähteenmäki PLA, Luukkainen T: Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41: 52-55.
45. Faculty of Sexual and Reproductive Healthcare: Clinical Guideline. Contraceptive Choices for Young People. March 2010. http://www.fsrh.org/pdfs/ ceuGuidance-YoungPeople2010.pdf.
46. National Institute for Health and Clinical Excellence (NICE): Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. 2005. http://www.nice.org.uk/pdf/CG030 fullguideline.pdf.
47. Stewart A, Cummins C, Gold L, et al: The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001; 108: 74-86.
48. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O: A levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257-263.
49. Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485-488.
50. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG: Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003; 80: 305-309.
51. British National Formulary for Children 2011-2012, p 406.
52. Faculty of Sexual and Reproductive Healthcare: Clinical Guideline. Progestogen-Only Injectable Contraception. November 2008. http://www.fsrh.org/ pdfs/CEUGuidance ProgestogenOnlyInjectables09.pdf.
53. Gordon CM, Pitts SAB: Approach to the Adolescent Requesting Contraception. J Clin Endocrinol Metab 2012; 97: 9-15.
54. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP: Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2004; 17: 17-21.
55. Zacharin MR: Puberty, contraception and hormonal management for young people with disabilities. Clin Pediatr 2009; 48: 149-155.
56. http://www.medicines.org.uk/EMC/medicine/11121/SPC/Depo-Provera+150mg+ ml+Injection/.
57. Zacharin M, Savasi I, Grover S: The impact of menstruation in adolescents with disabilities related to cerebral palsy. Arch Dis Child 2010; 95: 526-530.